A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma (Q30427677)

12 October 2017

A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma (English)

1 reference

12 October 2017

1 reference

12

David A Reardon

1 reference

12 October 2017

1

Patrick Y Wen

1 reference

12 October 2017

3

Timothy F Cloughesy

1 reference

12 October 2017

David Schiff

2

1 reference

12 October 2017

Jeffrey J Raizer

4

1 reference

12 October 2017

John Laterra

5

1 reference

12 October 2017

Melanie Smitt

6

1 reference

12 October 2017

Michael Wolf

7

1 reference

12 October 2017

Kelly S Oliner

8

1 reference

12 October 2017

Abraham Anderson

9

1 reference

12 October 2017

Min Zhu

10

1 reference

12 October 2017

Elwyn Loh

11

1 reference

12 October 2017

language of work or name

1 reference

4 February 2011

1 reference

12 October 2017

1 reference

12 October 2017

13

1 reference

12 October 2017

4

1 reference

12 October 2017

437-446

1 reference

Bevacizumab salvage therapy following progression in high-grade glioma patients treated with VEGF receptor tyrosine kinase inhibitors

12 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3064694

Treatment of recurrent high-grade gliomas

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3064694

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3064694

EGFRvIII and c-Met pathway inhibitors synergize against PTEN-null/EGFRvIII+ glioblastoma xenografts.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3064694

Angiogenesis as a therapeutic target in malignant gliomas

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3064694

Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3064694

Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3064694

Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3064694

Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3064694

Adult gliosarcoma: epidemiology, natural history, and factors associated with outcome

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3064694

Malignant gliomas in adults

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3064694

Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3064694

AMG 102, a fully human anti-hepatocyte growth factor/scatter factor neutralizing antibody, enhances the efficacy of temozolomide or docetaxel in U-87 MG cells and xenografts

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3064694

Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3064694

A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3064694

Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3064694

Systemic anti-hepatocyte growth factor monoclonal antibody therapy induces the regression of intracranial glioma xenografts

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3064694

Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3064694

Targeting the c-Met pathway potentiates glioblastoma responses to gamma-radiation

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3064694

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3064694

Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3064694

Met and hepatocyte growth factor/scatter factor expression in human gliomas

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3064694

The trends in incidence of primary brain tumors in the population of Rochester, Minnesota.

20 June 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOQ198

In vivo targeting of SF/HGF and c-met expression via U1snRNA/ribozymes inhibits glioma growth and angiogenesis and promotes apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOQ198

Effects of hepatocyte growth factor (HGF) on human glioma cells in vitro: HGF acts as a motility factor in glioma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOQ198

Hepatocyte growth factor is associated with poor prognosis of malignant gliomas and is a predictor for recurrence of meningioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOQ198

Prognostic significance of c-Met expression in glioblastomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOQ198

Hepatocyte growth factor in cerebrospinal fluid is associated with mortality and recurrence of glioblastoma, and could be of prognostic value.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOQ198

Development of a real-time RT-PCR assay for detecting EGFRvIII in glioblastoma samples

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOQ198

THE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOQ198

A phase Ib study of AMG 102 in combination with bevacizumab or motesanib in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOQ198

A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOQ198

Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOQ198

Scatter factor/hepatocyte growth factor protects against cytotoxic death in human glioblastoma via phosphatidylinositol 3-kinase- and AKT-dependent pathways.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3064694

Response criteria for phase II studies of supratentorial malignant glioma

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3064694

Safety, pharmacokinetics, and pharmacodynamics of AMG 102, a fully human hepatocyte growth factor-neutralizing monoclonal antibody, in a first-in-human study of patients with advanced solid tumors

26 November 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21297127

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Analysis of EGFR overexpression, EGFR gene amplification and the EGFRvIII mutation in Portuguese high-grade gliomas

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21297127

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1093/NEUONC/NOQ198

1 reference

12 October 2017

1 reference

12 October 2017

1 reference